Literature DB >> 16368383

Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.

Yukinori Sakao1, Hideaki Miyamoto, Akio Yamazaki, Tsumin Oh, Ryuta Fukai, Kazu Shiomi, Yuichi Saito.   

Abstract

BACKGROUND: We have tried to clarify the prognostic significance of metastasis to the highest mediastinal (HM) lymph node in patients with N2 lung cancer who underwent complete dissection of superior mediastinal (including HM) lymph nodes.
METHODS: This study analyzed 53 patients with N2 nonsmall cell lung cancer who underwent surgical procedures such as lobectomy plus hilar and mediastinal node dissection (T4, neoadjuvant therapy cases were excluded). For patients whose cancer was in the left lung, we performed surgery through the median sternotomy in order to dissect superior mediastinal nodes. The clinicopathologic records of the patients were examined for prognostic factors such as age, sex, side, histology, tumor location, tumor size, clinical node (cN) number, preoperative serum carcinoembryonic antigen level, number of metastatic stations, and HM lymph node involvement.
RESULTS: A univariate analysis showed that tumor size (T1/T2-3), cN factor (cN1-2/cN0), N2 level (multiple/single), and metastasis to the HM node were significant prognostic factors. In the multivariate analysis, metastasis to the HM lymph node remained a significant prognostic factor (p = 0.026). The 3-year survival rates were 52% in patients without metastasis to the HM lymph node and 21% in patients with metastasis to the HM lymph node (p < 0.001). Furthermore, when HM nodal involvement was absent, the 5-year survival rate was 33% even in patients with multilevel N2 status, 45% in patients with cN1-2 status, and 47% in patients with pT2-3 tumor status.
CONCLUSIONS: Highest mediastinal lymph node involvement is prognostic of highly advanced N2 disease resulting in poor outcome. The results also suggest that patients with no involvement of the HM lymph node can experience acceptable postoperative outcomes even if they have multilevel N2 status, positive cN status, or T2-3 tumor status.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368383     DOI: 10.1016/j.athoracsur.2005.06.077

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

1.  Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.

Authors:  Chi-Fu Jeffrey Yang; Syed M Adil; Kevin L Anderson; Robert Ryan Meyerhoff; Ryan S Turley; Matthew G Hartwig; David H Harpole; Betty C Tong; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  Eur J Cardiothorac Surg       Date:  2015-12-30       Impact factor: 4.191

2.  Anatomical variations in lymphatic drainage of the right lung: applications in lung cancer surgery.

Authors:  Assane Ndiaye; V Di-Marino; P S Ba; Aï Ndiaye; M Gaye; S Nazarian
Journal:  Surg Radiol Anat       Date:  2016-05-05       Impact factor: 1.246

3.  The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer.

Authors:  Daniel C Thomas; Brian N Arnold; Joshua E Rosen; Michelle C Salazar; Frank C Detterbeck; Justin D Blasberg; Daniel J Boffa; Anthony W Kim
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

4.  Prognostic role of station 3A mediastinal nodes for non-small-cell lung cancers.

Authors:  Hui Zheng; Wen Gao; Ke Fei; Hui-Kang Xie; Ge-Ning Jiang; Jia-An Ding; Chao Li; Chang Chen; Lei Zhang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-19

5.  Risk factors for recurrence after complete resection of pathological stage N2 non-small cell lung cancer.

Authors:  Guangliang Qiang; Chaoyang Liang; Qiduo Yu; Fei Xiao; Zhiyi Song; Yanchu Tian; Bin Shi; Deruo Liu; Yongqing Guo
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

6.  Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.

Authors:  Masaya Tamura; Isao Matsumoto; Daisuke Saito; Shuhei Yoshida; Munehisa Takata; Hirofumi Takemura
Journal:  World J Surg Oncol       Date:  2016-11-25       Impact factor: 2.754

Review 7.  Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment.

Authors:  Debora Brascia; Giulia De Iaco; Marcella Schiavone; Teodora Panza; Francesca Signore; Alessandro Geronimo; Doroty Sampietro; Michele Montrone; Domenico Galetta; Giuseppe Marulli
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

8.  Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer.

Authors:  Qin Zhang; Xu-Wei Cai; Wen Feng; Wen Yu; Xiao-Long Fu
Journal:  Ann Transl Med       Date:  2020-03

9.  The Prognosis According to Patterns of Mediastinal Lymph Node Metastasis in Pathologic Stage IIIA/N2 Non-Small Cell Lung Cancer.

Authors:  Do Wan Kim; Ju Sik Yun; Sang Yun Song; Kook Joo Na
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-02-05

10.  Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.

Authors:  Melissa A L Vyfhuis; Neha Bhooshan; Whitney M Burrows; Michelle Turner; Mohan Suntharalingam; James Donahue; Elizabeth M Nichols; Josephine Feliciano; Søren M Bentzen; Shahed Badiyan; Shamus R Carr; Joseph Friedberg; Charles B Simone; Martin J Edelman; Steven J Feigenberg; Pranshu Mohindra
Journal:  Adv Radiat Oncol       Date:  2017-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.